Abstract
A phase II study of 3-deazauridine (DAUR) showed poor activity in previously treated patients with advanced colorectal adenocarcinoma. There were no responses among 15 patients treated on a dose schedule of 1200 mg/m2/day for 5 days repeated at 3-week intervals. Toxicity included mild nausea and vomiting, occasional mucositis, diarrhea, and dizziness. A minimal degree of myelosuppression was observed.
Publication types
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
3-Deazauridine / administration & dosage*
-
3-Deazauridine / adverse effects
-
Adenocarcinoma / drug therapy*
-
Adult
-
Aged
-
Antineoplastic Agents / administration & dosage*
-
Antineoplastic Agents / adverse effects
-
Colonic Neoplasms / drug therapy*
-
Digestive System / drug effects
-
Drug Evaluation
-
Female
-
Humans
-
Male
-
Middle Aged
-
Rectal Neoplasms / drug therapy*
-
Uridine / analogs & derivatives*
Substances
-
Antineoplastic Agents
-
3-Deazauridine
-
Uridine